Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02272413 · ClinicalTrials.gov registry record · Phase 3
Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 671
- Enrollment target
NCT02272413 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 671 participants.
The verdict
NCT02272413, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 671 participants
- Enrollment target
Study Summary
The objective of this phase III trial is to establish statistical equivalence in terms of efficacy (best overall response rate \[ORR\], proportion of patients with complete response \[CR\] plus partial response \[PR\]) until 18 weeks of first-line treatment with BI 695502 plus chemotherapy versus Avastin® plus chemotherapy followed by maintenance monotherapy with either BI 695502 or Avastin®.
Interventions
- DRUG Avastin
- DRUG BI 695502
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 671 participants |
| Start Date | 2015-07-08 |
| Est. Completion | 2018-11-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02272413
The ClinicalTrials.gov registry entry for NCT02272413 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 671 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Avastin is the first listed.
NCT02272413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02272413 about?
NCT02272413 is a clinical study titled "Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer". The objective of this phase III trial is to establish statistical equivalence in terms of efficacy (best overall response rate \[ORR\], proportion of patients with complete response \[CR\] plus partial response \[PR\]) until 18 weeks of first-line treatment with BI 695502 plus chemotherapy versus Av...
What is the current status of trial NCT02272413?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 671 participants. The study started on 2015-07-08. Estimated completion is 2018-11-16.
What interventions are being tested in trial NCT02272413?
The interventions under investigation include: Avastin (DRUG), BI 695502 (DRUG).
Who is sponsoring clinical trial NCT02272413?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.